"The excellent results obtained in our experimental program into ocular toxoplasmosis now confirms prior, differently - demonstrated efficacy of our vaccine VFOtx-251 and so strengthens our product portfolio in human health", explains Dr. Edouard Sèche, Head of Research of VitamFero. "To our knowledge, it is the very first time that an anti-toxoplasmosis vaccine has demonstrated such efficacy in prevention of ocular toxoplasmosis."